Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: Results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

Journal of Neuro-Oncology

Volumn 101, Issue 1, 2011, Pages 57-66

  Reardon, David A ^a   Vredenburgh, James J ^a   Desjardins, Annick ^a   Peters, Katherine ^a   Gururangan, Sridharan ^a   Sampson, John H ^a   Marcello, Jennifer ^a   Herndon II, James E ^a   McLendon, Roger E ^a   Janney, Dorothea ^a   Friedman, Allan H ^a   Bigner, Darell D ^a   Friedman, Henry S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Glioblastoma; Raf; Sorafenib; Temozolomide; VEGF

Indexed keywords

BEVACIZUMAB; CYTOCHROME P450 3A; DEXAMETHASONE; SORAFENIB; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN INHIBITOR;

ADULT; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; FATIGUE; FEMALE; GLIOBLASTOMA; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INFECTION; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; RECURRENT CANCER; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION;

ADULT; AGED; ANTICONVULSANTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BRAIN NEOPLASMS; CYTOCHROME P-450 CYP3A; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PYRIDINES; RECURRENCE;

EID: 79751535045     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0217-6     Document Type: Article

References (62)

1. ET Wong KR Hess MJ Gleason KA Jaeckle AP Kyritsis MD Prados VA Levin WK Yung 1999 Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 2572 2578 1:STN:280: DC%2BD3c%2FjtVSmsQ%3D%3D 10561324
2. KR Lamborn WK Yung SM Chang PY Wen TF Cloughesy LM Deangelis HI Robins FS Lieberman HA Fine KL Fink L Junck L Abrey MR Gilbert M Mehta JG Kuhn KD Aldape J Hibberts PM Peterson MD Prados 2008 Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas Neuro-oncology 10 162 170 10.1215/15228517-2007-062 18356283
3. KV Ballman JC Buckner PD Brown C Giannini PJ Flynn BR LaPlant KA Jaeckle 2007 The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Neuro-oncology 9 29 38 1:CAS:528:DC%2BD2sXht1Ojs7w%3D 10.1215/15228517-2006-025 17108063 (Pubitemid 46543486)
4. JJ Vredenburgh A Desjardins JE Herndon II JM Dowell DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan M Wagner DD Bigner AH Friedman HS Friedman 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259 1:CAS:528:DC%2BD2sXhvF2htr8%3D 10.1158/1078-0432.CCR-06-2309 17317837 (Pubitemid 46424067)
5. JJ Vredenburgh A Desjardins JE Herndon II J Marcello DA Reardon JA Quinn JN Rich S Sathornsumetee S Gururangan J Sampson M Wagner L Bailey DD Bigner AH Friedman HS Friedman 2007 Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 4722 4729 1:CAS:528:DC%2BD2sXhtlCgsLjF 10.1200/JCO.2007.12.2440 17947719 (Pubitemid 350086473)
6. A Desjardins DA Reardon JE Herndon II J Marcello JA Quinn JN Rich S Sathornsumetee S Gururangan J Sampson L Bailey DD Bigner AH Friedman HS Friedman JJ Vredenburgh 2008 Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas Clin Cancer Res 14 7068 7073 1:CAS:528:DC%2BD1cXhtlens7fJ 10.1158/1078-0432.CCR-08-0260 18981004
7. HS Friedman MD Prados PY Wen T Mikkelsen D Schiff LE Abrey WK Yung N Paleologos MK Nicholas R Jensen J Vredenburgh J Huang M Zheng T Cloughesy 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 4733 4740 1:CAS:528:DC%2BD1MXhtlGgtbbM 10.1200/JCO.2008.19.8721 19720927
8. TN Kreisl L Kim K Moore P Duic C Royce I Stroud N Garren M Mackey JA Butman K Camphausen J Park PS Albert HA Fine 2009 Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 740 745 1:CAS:528:DC%2BD1MXjsVCjs7o%3D 10.1200/JCO.2008.16.3055 19114704
9. TT Batchelor AG Sorensen E di Tomaso WT Zhang DG Duda KS Cohen KR Kozak DP Cahill PJ Chen M Zhu M Ancukiewicz MM Mrugala S Plotkin J Drappatz DN Louis P Ivy DT Scadden T Benner JS Loeffler PY Wen RK Jain 2007 AZD2171, a Pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 83 95 1:CAS:528: DC%2BD2sXhtFClsLc%3D 10.1016/j.ccr.2006.11.021 17222792 (Pubitemid 46075199)
10. S Wilhelm C Carter M Lynch T Lowinger J Dumas RA Smith B Schwartz R Simantov S Kelley 2006 Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 835 844 1:CAS:528: DC%2BD28XhtVajsbbM 10.1038/nrd2130 17016424 (Pubitemid 44480537)
11. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 1:CAS:528:DC%2BD2sXksVKitg%3D%3D 10.1056/NEJMoa060655 17215530 (Pubitemid 46089673)
12. JM Llovet S Ricci V Mazzaferro P Hilgard E Gane JF Blanc AC de Oliveira A Santoro JL Raoul A Forner M Schwartz C Porta S Zeuzem L Bolondi TF Greten PR Galle JF Seitz I Borbath D Haussinger T Giannaris M Shan M Moscovici D Voliotis J Bruix 2008 Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378 390 1:CAS:528:DC%2BD1cXovFWjsL8%3D 10.1056/NEJMoa0708857 18650514
13. BJ Denny RT Wheelhouse MF Stevens LL Tsang JA Slack 1994 NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA Biochemistry 33 9045 9051 1:CAS:528:DyaK2cXkvF2hsbs%3D 10.1021/bi00197a003 8049205
14. ES Newlands MF Stevens SR Wedge RT Wheelhouse C Brock 1997 Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials Cancer Treat Rev 23 35 61 1:CAS:528:DyaK2sXktFOrt7w%3D 10.1016/S0305-7372(97)90019-0 9189180 (Pubitemid 27273454)
15. CS Brock ES Newlands SR Wedge M Bower H Evans I Colquhoun M Roddie M Glaser MH Brampton GJ Rustin 1998 Phase I trial of temozolomide using an extended continuous oral schedule Cancer Res 58 4363 4367 1:CAS:528: DyaK1cXmsVyqsbg%3D 9766665
16. A Wick J Felsberg JP Steinbach U Herrlinger M Platten B Blaschke R Meyermann G Reifenberger M Weller W Wick 2007 Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma J Clin Oncol 25 3357 3361 1:CAS:528:DC%2BD2sXhtVWqs7nO 10.1200/JCO.2007.10.7722 17664483 (Pubitemid 47325623)
17. JR Perry P Rizek R Cashman M Morrison T Morrison 2008 Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach Cancer 113 2152 2157 1:CAS:528:DC%2BD1cXht12lu77J 10.1002/cncr.23813 18756530
18. B Neyns C Chaskis E Joosens J Menten L D'Hondt F Branle J Sadones A Michotte 2008 A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma Cancer Invest 26 269 277 1:CAS:528:DC%2BD1cXislalsrk%3D 10.1080/ 07357900701708393 18317968 (Pubitemid 351329006)
19. AA Brandes A Tosoni G Cavallo R Bertorelle V Gioia E Franceschi M Biscuola V Blatt L Crino M Ermani 2006 Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO) Br J Cancer 95 1155 1160 1:CAS:528:DC%2BD28XhtFChs73O 10.1038/sj.bjc.6603376 17024124 (Pubitemid 44658477)
20. C Balmaceda D Peereboom S Pannullo YK Cheung PG Fisher J Alavi M Sisti J Chen RL Fine 2008 Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas Cancer 112 1139 1146 1:CAS:528:DC%2BD1cXjs1eqsbw%3D 10.1002/cncr.23167 18246536 (Pubitemid 351304600)
21. W Wick M Platten M Weller 2009 New (alternative) temozolomide regimens for the treatment of glioma Neuro-oncology 11 69 79 1:CAS:528: DC%2BD1MXjtFKntr8%3D 10.1215/15228517-2008-078 18772354
22. AM Spence RA Peterson JD Scharnhorst DL Silbergeld RC Rostomily 2004 Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas J Neurooncol 70 91 95 10.1023/B:NEON.0000040837.68411.97 15527114 (Pubitemid 39194004)
23. RB Khan JJ Raizer MG Malkin KA Bazylewicz LE Abrey 2002 A phase II study of extended low-dose temozolomide in recurrent malignant gliomas Neuro-oncology 4 39 43 1:CAS:528:DC%2BD38XktlGltL4%3D 11772431
24. DS Kong JI Lee WS Kim MJ Son H Lim do ST Kim K Park JH Kim W Eoh DH Nam 2006 A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma Oncol Rep 16 1117 1121 1:CAS:528:DC%2BD28Xht1erurbO 17016602
25. A Berrocal P Perez Segura M Gil C Balana J Garcia Lopez R Yaya J Rodriguez G Reynes O Gallego L Iglesias 2010 Extended-schedule dose-dense temozolomide in refractory gliomas J Neurooncol 96 3 417 422 1:CAS:528:DC%2BC3cXpsVaqsQ%3D%3D 10.1007/s11060-009-9980-7 19669096
26. DR Macdonald TL Cascino SC Schold Jr. JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840
27. WK Yung MD Prados R Yaya-Tur SS Rosenfeld M Brada HS Friedman R Albright J Olson SM Chang AM O'Neill AH Friedman J Bruner N Yue M Dugan S Zaknoen VA Levin 1999 Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group J Clin Oncol 17 2762 2771 1:CAS:528:DyaK1MXmtlWru7s%3D 10561351
28. SM Wilhelm L Adnane P Newell A Villanueva JM Llovet M Lynch 2008 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol Cancer Ther 7 3129 3140 1:CAS:528:DC%2BD1cXht1ensLfE 10.1158/1535-7163.MCT-08-0013 18852116
29. H Davies GR Bignell C Cox P Stephens S Edkins S Clegg J Teague H Woffendin MJ Garnett W Bottomley N Davis E Dicks R Ewing Y Floyd K Gray S Hall R Hawes J Hughes V Kosmidou A Menzies C Mould A Parker C Stevens S Watt S Hooper R Wilson H Jayatilake BA Gusterson C Cooper J Shipley D Hargrave K Pritchard-Jones N Maitland G Chenevix-Trench GJ Riggins DD Bigner G Palmieri A Cossu A Flanagan A Nicholson JW Ho SY Leung ST Yuen BL Weber HF Seigler TL Darrow H Paterson R Marais CJ Marshall R Wooster MR Stratton PA Futreal 2002 Mutations of the BRAF gene in human cancer Nature 417 949 954 1:CAS:528:DC%2BD38XkvVagsLo%3D 10.1038/nature00766 12068308 (Pubitemid 34716871)
30. CE Pelloski E Lin L Zhang WK Yung H Colman JL Liu SY Woo AB Heimberger D Suki M Prados S Chang FG Barker III GN Fuller KD Aldape 2006 Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma Clin Cancer Res 12 3935 3941 1:CAS:528:DC%2BD28XmsValtLs%3D 10.1158/1078-0432.CCR-05-2202 16818690 (Pubitemid 44078078)
31. O Martinho A Longatto-Filho MB Lambros A Martins C Pinheiro A Silva F Pardal J Amorim A Mackay F Milanezi N Tamber K Fenwick A Ashworth JS Reis-Filho JM Lopes RM Reis 2009 Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas Br J Cancer 101 973 982 1:CAS:528:DC%2BD1MXhtV2qsrjF 10.1038/sj.bjc.6605225 19707201
32. M Hermanson K Funa M Hartman L Claesson-Welsh CH Heldin B Westermark M Nister 1992 Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops Cancer Res 52 3213 3219 1:CAS:528: DyaK38Xkt1Cjsbw%3D 1317261
33. AH Shih C Dai X Hu MK Rosenblum JA Koutcher EC Holland 2004 Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis Cancer Res 64 4783 4789 1:CAS:528:DC%2BD2cXls1Omsb4%3D 10.1158/0008-5472.CAN-03-3831 15256447 (Pubitemid 38924521)
34. H Joensuu M Puputti H Sihto O Tynninen NN Nupponen 2005 Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme J Pathol 207 224 231 1:CAS:528:DC%2BD2MXhtFKnsr%2FO 10.1002/path.1823 16021678 (Pubitemid 41404153)
35. M Puputti O Tynninen H Sihto T Blom H Maenpaa J Isola A Paetau H Joensuu NN Nupponen 2006 Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas Mol Cancer Res 4 927 934 1:CAS:528:DC%2BD28XhtlCrtr3I 10.1158/1541-7786.MCR-06-0085 17189383 (Pubitemid 46121551)
36. Nabors LB, Rosenfeld MG, Chamberlain SC, Phuphanich S, Batchelor T, Supko JG, Desideri S, Xiaobu Y, Wright J, Grossman S (2007) A Phase I trial of sorafenib (BAY 743-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401). 2007 ASCO Annual Meeting Proceedings, Chicago, IL, p 89 s
37. Prados M, Gilbert M, Kuhn K, Lamborn K, Cloughesy T, Lieberman F, Puduvalli VK, Robins HI, Lassman A, Wen PY (2009) Phase I/II study of sorefenib and erlotinib for patients with recurrent glioblastoma (GBM)(NABTC 05-02). American Society of Clinical Oncology, Orlando, FL, p 88 s
38. Wen PY, Cloughesy T, Kuhn J, Lamborn K, Abrey LE, Lieberman F, Robins HI, Wright J, Prados MD, Gilbert M (2009) Phase I/II study of sorafenib and temsirolimus for patients with recurrent glioblastoma (GBM)(NABTC 05-02). American Society of Clinical Oncology, Orlando, FL, p 88 s
39. AW Tolcher SL Gerson L Denis C Geyer LA Hammond A Patnaik AD Goetz G Schwartz T Edwards L Reyderman P Statkevich DL Cutler EK Rowinsky 2003 Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88 1004 1011 1:CAS:528:DC%2BD3sXisFahtrY%3D 10.1038/sj.bjc.6600827 12671695 (Pubitemid 36560766)
40. A Tosoni G Cavallo M Ermani L Scopece E Franceschi C Ghimenton M Gardiman L Pasetto V Blatt AA Brandes 2006 Is protracted low-dose temozolomide feasible in glioma patients? Neurology 66 427 429 1:CAS:528:DC%2BD28Xnt1Crsg%3D%3D 10.1212/01.wnl.0000196465.83423.ec 16476947 (Pubitemid 43739951)
41. JR Perry K Belanger WP Mason D Fulton P Kavan J Easaw C Shields S Kirby DR Macdonald DR Macdonald DD Eisenstat B Thiessen P Forsyth J-F Pouliot 2010 A phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma. RESCUE study J Clin Oncol 28 12 2051 2057 1:CAS:528:DC%2BC3cXmtlSksrk%3D 10.1200/JCO.2009.26.5520 20308655
42. LL Siu A Awada CH Takimoto M Piccart B Schwartz T Giannaris C Lathia O Petrenciuc MJ Moore 2006 Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer Clin Cancer Res 12 144 151 1:CAS:528:DC%2BD28Xht1Gmuw%3D%3D 10.1158/1078-0432.CCR-05-1571 16397036 (Pubitemid 43166188)
43. Flaherty KT, Brose M, Schuchter L et al (2004) Phase I/II trial of BAY 43-9006, carboplatin and paclitaxel demonstrated preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. J Clin Oncol, p 711 s
44. H Richly P Kupsch K Passage M Grubert RA Hilger R Voigtmann B Schwartz E Brendel O Christensen CG Haase D Strumberg 2004 Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer Int J Clin Pharmacol Ther 42 650 651 1:STN:280:DC%2BD2cnit1yqsA%3D%3D 15598035
45. P Kupsch BF Henning K Passarge H Richly K Wiesemann RA Hilger ME Scheulen O Christensen E Brendel B Schwartz E Hofstra R Voigtmann S Seeber D Strumberg 2005 Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer Clin Colorectal Cancer 5 188 196 10.3816/CCC.2005.n.030 16197622
46. A Hauschild SS Agarwala U Trefzer D Hogg C Robert P Hersey A Eggermont S Grabbe R Gonzalez J Gille C Peschel D Schadendorf C Garbe S O'Day A Daud JM White C Xia K Patel JM Kirkwood U Keilholz 2009 Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma J Clin Oncol 27 2823 2830 1:CAS:528:DC%2BD1MXosVehs7g%3D 10.1200/JCO.2007.15.7636 19349552
47. L Jilaveanu C Zito SJ Lee KL Nathanson RL Camp DL Rimm KT Flaherty HM Kluger 2009 Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib Clin Cancer Res 15 1076 1085 1:CAS:528:DC%2BD1MXht1Ons78%3D 10.1158/1078-0432.CCR-08-2280 19188183
48. RK Amaravadi LM Schuchter DF McDermott A Kramer L Giles K Gramlich M Carberry AB Troxel R Letrero KL Nathanson MB Atkins PJ O'Dwyer KT Flaherty 2009 Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases Clin Cancer Res 15 7711 7718 1:CAS:528: DC%2BD1MXhsFGgurjJ 10.1158/1078-0432.CCR-09-2074 19996224
49. AD Norden GS Young K Setayesh A Muzikansky R Klufas GL Ross AS Ciampa LG Ebbeling B Levy J Drappatz S Kesari PY Wen 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787 1:CAS:528:DC%2BD1cXitlyqs7o%3D 10.1212/01.wnl.0000304121.57857.38 18316689
50. EC Quant AD Norden J Drappatz A Muzikansky L Doherty D Lafrankie A Ciampa S Kesari PY Wen 2009 Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab Neuro-oncology 11 550 555 1:CAS:528:DC%2BD1MXhtlWht73P 10.1215/15228517-2009-006 19332770
51. JW Clark JP Eder D Ryan C Lathia HJ Lenz 2005 Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors Clin Cancer Res 11 5472 5480 1:CAS:528:DC%2BD2MXmvFSmtbY%3D 10.1158/1078-0432.CCR-04- 2658 16061863 (Pubitemid 41060823)
52. A Awada A Hendlisz T Gil S Bartholomeus M Mano D de Valeriola D Strumberg E Brendel CG Haase B Schwartz M Piccart 2005 Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours Br J Cancer 92 1855 1861 1:CAS:528:DC%2BD2MXkt1Sgsrw%3D 10.1038/sj.bjc.6602584 15870716 (Pubitemid 40826133)
53. C Lathia J Lettieri F Cihon M Gallentine M Radtke P Sundaresan 2006 Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics Cancer Chemother Pharmacol 57 685 692 1:CAS:528: DC%2BD28Xjs1KktLk%3D 10.1007/s00280-005-0068-6 16133532
54. GM Keating A Santoro 2009 Sorafenib: a review of its use in advanced hepatocellular carcinoma Drugs 69 223 240 1:CAS:528:DC%2BD1MXkvFClsb8%3D 10.2165/00003495-200969020-00006 19228077
55. M Moore HW Hirte L Siu A Oza SJ Hotte O Petrenciuc F Cihon C Lathia B Schwartz 2005 Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors Ann Oncol 16 1688 1694 1:STN:280:DC%2BD2MvpvFKjuw%3D%3D 10.1093/annonc/mdi310 16006586 (Pubitemid 41510145)
56. MR Gilbert JG Supko T Batchelor G Lesser JD Fisher S Piantadosi S Grossman 2003 Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma Clin Cancer Res 9 2940 2949 1:CAS:528:DC%2BD3sXmtF2iu7Y%3D 12912940
57. MD Prados WK Yung KA Jaeckle HI Robins MP Mehta HA Fine PY Wen TF Cloughesy SM Chang MK Nicholas D Schiff HS Greenberg L Junck KL Fink KR Hess J Kuhn 2004 Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study Neuro-oncology 6 44 54 1:CAS:528:DC%2BD2cXht1aqsr8%3D 10.1215/S1152851703000292 14769140 (Pubitemid 38139639)
58. M Santisteban JC Buckner JM Reid W Wu BW Scheithauer MM Ames SJ Felten DA Nikcevich M Wiesenfeld KA Jaeckle E Galanis North Central Cancer Treatment Group 2009 Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results J Neurooncol 92 2 165 175 1:CAS:528: DC%2BD1MXitFKntb8%3D 10.1007/s11060-008-9749-4 19066728
59. E Raymond AA Brandes C Dittrich P Fumoleau B Coudert PM Clement M Frenay R Rampling R Stupp JM Kros MC Heinrich T Gorlia D Lacombe MJ van den Bent 2008 Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study J Clin Oncol 26 4659 4665 1:CAS:528:DC%2BD1cXht1KqtLfL 10.1200/JCO.2008.16.9235 18824712
60. DA Reardon MJ Egorin JA Quinn JN Rich Sr I Gururangan JJ Vredenburgh A Desjardins S Sathornsumetee JM Provenzale JE Herndon II JM Dowell MA Badruddoja RE McLendon TF Lagattuta KP Kicielinski G Dresemann JH Sampson AH Friedman AJ Salvado HS Friedman 2005 Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme J Clin Oncol 23 9359 9368 1:CAS:528:DC%2BD28Xnt1ymsw%3D%3D 10.1200/JCO.2005.03.2185 16361636
61. PY Wen WK Yung KR Lamborn PL Dahia Y Wang B Peng LE Abrey J Raizer TF Cloughesy K Fink M Gilbert S Chang L Junck D Schiff F Lieberman HA Fine M Mehta HI Robins LM DeAngelis MD Groves VK Puduvalli V Levin C Conrad EA Maher K Aldape M Hayes L Letvak MJ Egorin R Capdeville R Kaplan AJ Murgo C Stiles MD Prados 2006 Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08 Clin Cancer Res 12 4899 4907 1:CAS:528:DC%2BD28XotFKgt70%3D 10.1158/1078-0432.CCR-06-0773 16914578 (Pubitemid 44338577)
62. MD Prados KR Lamborn S Chang E Burton N Butowski M Malec A Kapadia J Rabbitt MS Page A Fedoroff D Xie SK Kelley 2006 Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma Neuro-oncology 8 67 78 1:CAS:528:DC%2BD28Xps1amtw%3D%3D 10.1215/S1522851705000451 16443950 (Pubitemid 43154453)